SLC7A5 and neoplasm: An example of this approach is the generation of a high affinity LAT1 inhibitor of (JPH203/ KYT-0353), that inhibits tumour growth in vivo and is currently undergoing a Phase I clinical trial in humans (UMIN000016546) as a novel adjuvant treatment approach for solid tumours13.